St. James's Hospital

Kutatók

• HTHugo C Temperley

Futó vizsgálatok

• Toboroz

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· 2. fázis· Hoffmann-La Roche· Forrás

• Toboroz

  Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

  NCT07781644· 2. fázis· Hoffmann-La Roche· Forrás

• Toboroz

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás

• Toboroz

  Phase 3 Study of Azenosertib Versus Chemotherapy in Platinum-Resistant Ovarian Cancers Positive for Cyclin E1 Protein Expression

  2025-524641-27-00· 3. fázis· K-Group Beta Inc.· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· 3. fázis· Hoffmann-La Roche· Forrás

• Toboroz

  A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

  NCT07843498· 3. fázis· Hoffmann-La Roche· Forrás

• Toboroz

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· 3. fázis· Takeda· Forrás

• Toboroz

  Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer

  NCT07564141· 3. fázis· Genmab· Forrás

• Toboroz

  Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

  NCT07158489· 2. fázis· Swiss Cancer Institute· Forrás

• Toboroz

  A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

  NCT07720375· 2. fázis· UCB Biopharma SRL· Forrás

• Toboroz

  A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

  NCT07656415· 3. fázis· Agios Pharmaceuticals, Inc.· Forrás

• Toboroz

  Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

  NCT07489066· 2. fázis· Pfizer· Forrás

• Toboroz

  MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab

  NCT07024706· 2. fázis· AstraZeneca· Forrás

• Toboroz

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· 3. fázis· Summit Therapeutics Inc.· Forrás

• Még nem toboroz

  HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before

  2025-524230-25-00· 2. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás

• Még nem toboroz

  A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer

  NCT07455422· University Hospital, Antwerp· Forrás

• Toboroz

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· 3. fázis· Takeda· Forrás

• Toboroz

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

  NCT07416604· 3. fázis· Hoffmann-La Roche· Forrás

• Toboroz

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás

• Toboroz

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· 3. fázis· Bristol-Myers Squibb· Forrás

• Toboroz

  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT07218341· 4. fázis· Eli Lilly and Company· Forrás

• Toboroz

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás

• Toboroz

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines

  NCT07561957· St. James's Hospital, Ireland· Forrás

• Toboroz

  A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

  NCT06931717· 3. fázis· ETOP IBCSG Partners Foundation· Forrás

• Toboroz

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· 3. fázis· Eli Lilly and Company· Forrás

• Toboroz

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· 3. fázis· Eli Lilly and Company· Forrás

• Toboroz

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· 3. fázis· Novo Nordisk A/S· Forrás

• Toboroz

  Obstructive Sleep Apnoea and Difficult Asthma (OSADA)

  NCT07160868· St. James's Hospital, Ireland· Forrás

• Toboroz

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· 3. fázis· Relay Therapeutics, Inc.· Forrás

• Toboroz

  A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer

  NCT06523374· University Hospital, Antwerp· Forrás

• Toboroz

  A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.

  2024-512753-24-00· 3. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás

• Toboroz

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· 3. fázis· Alnylam Pharmaceuticals· Forrás

• Toboroz

  A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)

  2023-510294-34-00· 3. fázis· University Of Cologne· Forrás

• Toboroz

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· 3. fázis· BeOne Medicines· Forrás

• Toboroz

  Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

  NCT05974774· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás

• Toboroz

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás

• Fut, nem toboroz

  A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

  NCT06924970· 2. fázis· Agios Pharmaceuticals, Inc.· Forrás

• Fut, nem toboroz

  Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clinical trial.

  2024-513958-29-00· 3. fázis· Trinity College Dublin· Forrás

• Toboroz

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· 3. fázis· Mirati Therapeutics Inc.· Forrás

• Toboroz

  A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  NCT06890884· 2. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  NCT06824467· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· 2/3. fázis· Bicara Therapeutics· Forrás

• Toboroz

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· 3. fázis· ETOP IBCSG Partners Foundation· Forrás

• Fut, nem toboroz

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· 3. fázis· Pfizer· Forrás

• Fut, nem toboroz

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· 3. fázis· Genmab· Forrás

Showing 50 of 97.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák15 toboroz
• Petefészekrák7 toboroz
• Akut mieloid leukémia (AML)4 toboroz
• Gyomor- és nyelőcsőrák4 toboroz
• Krónikus limfoid leukémia (CLL)4 toboroz
• Gyermekkori daganatok3 toboroz
• Amiloidózis2 toboroz
• Áttétes emlőrák2 toboroz
• Barrett's oesophagus2 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)2 toboroz
• Vastagbélrák2 toboroz
• Akut limfoid leukémia (ALL)1 toboroz
• Alzheimer-kór1 toboroz
• Asztma1 toboroz
• Bronchiectasis1 toboroz
• Cisztás fibrózis1 toboroz
• Elhízás1 toboroz
• Fej-nyaki daganatok1 toboroz
• Hasnyálmirigyrák1 toboroz
• Hemofília1 toboroz
• HIV-fertőzés1 toboroz
• Hodgkin-limfóma1 toboroz
• Immune thrombocytopenia (ITP)1 toboroz
• Krónikus vesebetegség1 toboroz
• Máj- és epeúti rák1 toboroz
• Méhnyakrák1 toboroz
• Méhtestrák1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Mieloproliferatív neopláziák1 toboroz
• Nephrotic syndrome1 toboroz
• Obstructive sleep apnoea1 toboroz
• Parkinson-kór1 toboroz
• Prosztatarák1 toboroz
• Sarlósejtes vérszegénység1 toboroz
• Sclerosis multiplex (SM)1 toboroz
• Szarkóma1 toboroz
• Szívelégtelenség1 toboroz
• Tripla negatív emlőrák1 toboroz

Lezárt vizsgálatok

• Lezárult

  A multi-part, adaptive, Phase 1, first time in human study in healthy participants and participants with atopic dermatitis (AD) to assess the safety, tolerability, pharmacokinetics (PK) of single ascending (SAD), multiple ascending doses (MAD) and selected dose of SYX-5219 (AD Participants)

  2025-522216-17-00· 1. fázis· Sitryx Therapeutics Limited· Forrás

• Toboroz

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· 3. fázis· Incyte Corporation· Forrás

• Lezárult

  A Clinical Study of Mitapivat in Patients with Sickle Cell Disease and Kidney Disease

  NCT06286046· 2. fázis· Agios Pharmaceuticals Inc.· Forrás

• Lezárult

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás

• Lezárult

  A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

  NCT05870748· 2. fázis· Sutro Biopharma Inc.· Forrás

• Lezárult

  A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

  2023-509472-42-00· 3. fázis· Celgene International II S.a.r.l.· Forrás

• Fut, nem toboroz

  Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

  NCT06132958· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Clinical trial of MK-7648A in adults and children with skin cancer

  NCT05665595· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  An 18-month study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa

  2022-502921-16-00· 4. fázis· Swedish Orphan Biovitrum AB (publ)· Forrás

• Lezárult

  A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly with efanesoctocog alfa.

  2022-500275-31-00· 3. fázis· Swedish Orphan Biovitrum AB (publ)· Forrás

• Lezárult

  A Feasibility Trial for Circadian Rest-activity Rhythm Disorders in Cancer (RALI)

  NCT06329479· University of Dublin, Trinity College· Forrás

• Toboroz

  Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)

  2022-500699-76-00· 3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás

• Lezárult

  Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

  NCT05767034· 3. fázis· Novartis Pharmaceuticals· Forrás

• Lezárult

  A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

  NCT05394519· 3. fázis· Novo Nordisk A/S· Forrás

• Fut, nem toboroz

  A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

  NCT05458297· 2. fázis· Merck Sharp & Dohme LLC· Forrás

• Fut, nem toboroz

  Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

  NCT05360446· 3. fázis· Novartis Pharmaceuticals· Forrás

• Fut, nem toboroz

  Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

  NCT05224141· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· 3. fázis· Amgen· Forrás

• Fut, nem toboroz

  Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

  NCT05116189· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

  NCT05093933· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· 3. fázis· Novo Nordisk A/S· Forrás

• Lezárult

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· 3. fázis· Novo Nordisk A/S· Forrás

• Lezárult

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.

  NCT04464564· 3. fázis· Otsuka Pharmaceutical Development & Commercialization Inc.· Forrás

• Fut, nem toboroz

  An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

  NCT04717414· 3. fázis· Celgene· Forrás

• Fut, nem toboroz

  Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

  NCT04685135· 3. fázis· Mirati Therapeutics Inc.· Forrás

• Lezárult

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· 3. fázis· GlaxoSmithKline· Forrás

• Lezárult

  Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

  NCT04475939· 3. fázis· GlaxoSmithKline· Forrás

• Fut, nem toboroz

  A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

  2024-518318-25-00· 3. fázis· Alnylam Pharmaceuticals Inc.· Forrás

• Lezárult

  A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

  2023-505035-12-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás

• Lezárult

  A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

  NCT04026412· 3. fázis· Bristol-Myers Squibb· Forrás

• Lezárult

  An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

  NCT03952039· 3. fázis· Celgene· Forrás

• Lezárult

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· 3. fázis· Stemline Therapeutics, Inc.· Forrás

• Lezárult

  Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

  NCT03884101· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study

  NCT06274541· Cancer Trials Ireland· Forrás

• Lezárult

  Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

  NCT03754790· 3. fázis· Genzyme, a Sanofi Company· Forrás

• Lezárult

  Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

  NCT03675737· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

  NCT03615326· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

  NCT03607422· 3. fázis· AbbVie· Forrás

• Lezárult

  HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

  NCT03569891· 3. fázis· CSL Behring· Forrás

• Fut, nem toboroz

  Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

  NCT03425643· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Lezárult

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· 3. fázis· pharmaand GmbH· Forrás

• Lezárult

  A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

  NCT03069352· 3. fázis· AbbVie· Forrás

• Lezárult

  Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

  NCT02842086· 3. fázis· Gilead Sciences Inc.· Forrás

• Lezárult

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· 3. fázis· German CLL Study Group· Forrás

• Lezárult

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· 3. fázis· University College Dublin· Forrás

• Lezárult

  Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

  NCT02620280· 3. fázis· Fondazione Michelangelo· Forrás

• Lezárult

  Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

  NCT02504372· 3. fázis· Merck Sharp & Dohme LLC· Forrás

• Toboroz

  Breast Cancer Proteomics and Molecular Heterogeneity

  NCT01840293· Cancer Trials Ireland· Forrás

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Bronchiectasis14 munka · 1 vizsgálat
• Hemofília12 munka · 6 vizsgálat
• Mezotelióma6 munka · 0 vizsgálat